Literature DB >> 18949405

The phosphorylation of survivin Thr34 by p34cdc2 in carcinogenesis of oral submucous fibrosis.

Shanghui Zhou1, Lili Li, Xinchun Jian, Xinrong Ou, Haiying Jiang, Zhigang Yao, Chunjiao Xu, Jieying Peng.   

Abstract

Survivin is a crucial node molecule involved in apoptosis, cell division and drug discovery. Up-regulation of survivin in the tissues of oral submucous fibrosis (OSF) and oral squamous cell carcinoma (OSCC) originated from OSF has already been demonstrated. Survivin Thr34 phosphorylation is involved in the inhibition of apoptosis and cell division. To determine the potential involvement of survivin Thr34 phosphorylation in carcinogenesis of OSF, 40 OSFs, 42 OSCCs originated from OSF and 10 normal tissues from surgical specimens were studied. Immunohistochemistry showed that the positive staining rate of the survivin phosphorylation on Thr34 in OSCC originated from OSF group was significantly higher than that in OSF group (P<0.01), and none in the normal oral mucosa specimens. Survivin phosphorylation on Thr34 is predominantly located in the nucleus, which account for its function in apoptosis at cell division. Western blotting analysis showed increasing expression of survivin Thr34 phosphorylation, cyclin B1 and p34cdc2 in carcinogenesis of OSF. Furthermore, p34cdc2-cyclin B1 kinase was confirmed to phosphorylate survivin on Thr34 in carcinogenesis of OSF by immunoprecipitation and immunoblot. These results suggest that the phosphorylation of survivin on Thr34 critically regulate survivin and plays an important role during the malignant transformation of OSF, which will provide an indication to early diagnosis and therapy in carcinogenesis of OSF.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18949405

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  Oral administration of caffeine during voluntary exercise markedly decreases tissue fat and stimulates apoptosis and cyclin B1 in UVB-treated skin of hairless p53-knockout mice.

Authors:  Yourong Lou; Qingyun Peng; Bonnie Nolan; George C Wagner; Yaoping Lu
Journal:  Carcinogenesis       Date:  2009-11-19       Impact factor: 4.944

2.  Expression of Survivin in Oral Potentially Malignant Disorders: An Immunohistochemical Study.

Authors:  Venkatraman R Rajanna; Murali C Raveendranath; Shanmugam Kathiresan; Soundarya Srinivasan; Janani Ilango
Journal:  J Pharm Bioallied Sci       Date:  2020-08-28

3.  Survivin-T34A: molecular mechanism and therapeutic potential.

Authors:  Jonathan R Aspe; Nathan R Wall
Journal:  Onco Targets Ther       Date:  2010-12-06       Impact factor: 4.147

Review 4.  Survivin - biology and potential as a therapeutic target in oncology.

Authors:  Chun Hei Antonio Cheung; Chien-Chang Huang; Fang-Ying Tsai; Jane Ying-Chieh Lee; Siao Muk Cheng; Yung-Chieh Chang; Yi-Chun Huang; Shang-Hung Chen; Jang-Yang Chang
Journal:  Onco Targets Ther       Date:  2013-10-16       Impact factor: 4.147

Review 5.  Survivin as a preferential target for cancer therapy.

Authors:  Mahsa Mobahat; Aru Narendran; Karl Riabowol
Journal:  Int J Mol Sci       Date:  2014-02-13       Impact factor: 5.923

6.  In vivo antitumor activity of liposome‑plasmid DNA encoding mutant survivin‑T34A in cervical cancer.

Authors:  Fang Qiu; Xia Zhao
Journal:  Mol Med Rep       Date:  2018-05-11       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.